New hope for Crohn's patients when standard drugs fail
NCT ID NCT07310095
Summary
This study is testing a medication called guselkumab for people with Crohn's disease, a chronic inflammatory bowel condition, who have stopped responding to their current ustekinumab treatment. It will involve about 78 Chinese participants and will measure how well the new drug controls their symptoms and reduces intestinal inflammation over 48 weeks. The goal is to find an effective next option for managing this lifelong condition when first-line treatments fail.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital
RECRUITINGShanghai, 200031, China
-
Sir Run Run Shaw Hospital Zhejiang University School of Medicine
RECRUITINGHangzhou, 310018, China
-
The First Affiliated Hospital Sun Yat sen University
RECRUITINGGuangzhou, 510060, China
-
The Sixth Affiliated Hospital Sun Yat sen University
RECRUITINGGuangzhou, 510655, China
Conditions
Explore the condition pages connected to this study.